In RA development, IL-6 plays one of the key roles [39] and it has been proved by Hashizume et al. that IL-6 reduced the efficacy of MTX by decreasing the expression of SLC19A1 [43]. Here, SLC19A1 is linked to rheumatoid arthritis.